The selective inhibitors of BRAF V600, vemurafenib and dabrafenib have shown major tumour responses in about 50% of patients, resulting in improved progression free (PFS) and overall survival (OS) in MM compared with chemotherapy [5], [6]. Here, BRAF is linked to Miyoshi myopathy.